Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07658976 · ClinicalTrials.gov registry record · Phase 3
Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy
A Phase 3 study, sponsored by HIV Prevention Trials Network.
- Not yet
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT07658976 is a Phase 3 study that has not yet begun recruiting, run by HIV Prevention Trials Network. The registered enrollment target is 400 participants.
The verdict
NCT07658976, a Phase 3 study, has not yet begun recruiting, sponsored by HIV Prevention Trials Network.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV pre-exposure prophylaxis (PrEP) and sexually transmitted infection (STI) post-exposure prophylaxis (PEP) for Young Men
Interventions
- DRUG HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA
- DRUG STI PEP - Doxycycline as Doxy-PEP
- BEHAVIORAL 3P mHealth package
- BEHAVIORAL Handout about HIV PrEP options available at the site
- BEHAVIORAL Standard-of-care HIV PrEP counseling from qualified study staff
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2029-09-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07658976
The ClinicalTrials.gov registry entry for NCT07658976 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HIV Prevention Trials Network, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA is the first listed.
NCT07658976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07658976 about?
NCT07658976 is a clinical study titled "Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy". Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV pre-exposure prophylaxis (PrEP) and sexually transmitted infection (STI) post-exposure prophylaxis (PEP) for Young Men
What is the current status of trial NCT07658976?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2026-09-01. Estimated completion is 2029-09-01.
What interventions are being tested in trial NCT07658976?
The interventions under investigation include: HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA (DRUG), STI PEP - Doxycycline as Doxy-PEP (DRUG), 3P mHealth package (BEHAVIORAL), Handout about HIV PrEP options available at the site (BEHAVIORAL), Standard-of-care HIV PrEP counseling from qualified study staff (BEHAVIORAL).
Who is sponsoring clinical trial NCT07658976?
This trial is sponsored by HIV Prevention Trials Network, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.